Pulmonary embolism accounts for 10–15% of all paediatric venous thromboembolism (VTE) events, with an annual incidence of 0·14–0·9 per 100 000 children.1,2 Although rare, pulmonary embolism is a ...

The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...

Opportunities in the Medullary Thyroid Cancer market arise from diverse pipeline developments by 8+ companies. Focus areas include novel therapies like Regorafenib and next-gen RET inhibitors ...

Apollo Cancer Centres launches Shield™ Multi-Cancer Detection, a blood-based test that can detect signs of multiple cancers ...

This week's collection of venture capital financings in the biotech arena includes rounds for Celea, Beeline, Flare, Lycia, and Telum. PureTech's Celea eyes phase 3 for IPF drug a ...

Zydus and Apollo Hospitals collaborate to enhance access to a multi-cancer blood test for early detection in India.

Nairobi, July 2 (dpa/GNA) – Clinical testing of two antiviral therapy approaches against the Ebola virus is beginning in the Democratic Republic of the Congo, the World Health Organization (WHO) said ...

Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...

Zydus Lifesciences and Apollo Hospitals are rolling out Shield MCD in India for eligible adults aged 45 and above. The launch ...

Lucid Diagnostics offers asymmetric upside, with Medicare reimbursement as a near-term inflection point unlocking a $2–3M backlog. Read more on LUCD stock here.

The health agency is conducting a trial on the first potentially effective treatments for Bundibugyo virus, while adding the first diagnostic test to its emergency use list.

Healthcare organizations are under pressure to automate medical coding without compromising the security of protected health ...